Psychiatry Research: Neuroimaging
Volume 173, Issue 1 , Pages 63-70 , 15 July 2009

Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment

Received 31 October 2007 ,Revised 6 July 2008 ,Accepted 8 September 2008.

References 

  1. Achor RW. Depressions in hypertensive patients. I'll Heart Bulletin. 1959;8:105–107
  2. Albers, R.W., Siegel, G.J., (1999). 5. Membrane Transport. Basic neurochemistry : molecular, cellular, and medical aspects. G. J. Siegel. Philadelphia, Lippincott Williams & Wilkins: xxi, 1183.
  3. Albert PR. A functional promoter polymorphism of the 5HT1A receptor gene: association with depression and completed suicide. Biological Psychiatry. 2004;55:46S-46S
  4. American Psychiatric Association. and American Psychiatric Association. Task Force on DSM-IV . Diagnostic and Statistical Manual of Mental Disorders : DSM-IV. Washington, DC: American Psychiatric Association; 1994;
  5. Anderson AD, Oquendo MA, Parsey RV, Milak MS, Campbell C, Mann JJ. Regional brain responses to serotonin in major depressive disorder. Journal of Affective Disorders. 2004;82(3):411–417
  6. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Modern Problems of Pharmacopsychiatry. 1974;7(0):151–169
  7. Bhagwagar Z, Rabiner EA, Sargent PA, Grasby PM, Cowen PJ. Persistent reduction in brain serotonin1A receptor binding in recovered depressed men measured by positron emission tomography with [11C]WAY-100635. Molecular Psychiatry. 2004;9(4):386–392
  8. Brannan SK, Mayberg HS, McGinnis S, Silva JA, Tekell JL, Mahurin RK, et al. Cingulate metabolism predicts treatment response: a replication. Biological psychiatry. 2000;47:1S–173S
  9. Brody AL, Saxena S, Silverman DH, Alborzian S, Fairbanks LA, Phelps ME, et al. Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry Research. 1999;91(3):127–139
  10. Brody AL, Saxena S, Stoessel P, Gillies LA, Fairbanks LA, Alborzian S, et al. Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Archives of General Psychiatry. 2001;58(7):631–640
  11. Bschor T, Adli M, Baethge C, Eichmann U, Ising M, Uhr M, et al. Lithium augmentation increases the ACTH and cortisol response in the combined DEX/CRH test in unipolar major depression. Neuropsychopharmacology. 2002;27(3):470–478
  12. Buchsbaum MS, Wu J, Siegel BV, Hackett E, Trenary M, Abel L, et al. Effect of sertraline on regional metabolic rate in patients with affective disorder. Biological Psychiatry. 1997;41(1):15–22
  13. Bunney WE, Davis JM. Norepinephrine in depressive reactions. A review. Archives of General Psychiatry. 1965;13(6):483–494
  14. Coppen A. The biochemistry of affective disorders. British Journal of Psychiatry. 1967;113(504):1237–1264
  15. Coppen A. Defects in monoamine metabolism and their possible importance in the pathogenesis of depressive syndromes. British Journal of Psychiatry. 1969;72(2):173–180
  16. Dahlstrom M, Ahonen A, Ebeling H, Torniainen P, Heikkila J, Moilanen I. Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents. Molecular Psychiatry. 2000;5(5):514–522
  17. Drevets WC, Frank E, Price JC, Kupfer DJ, Holt D, Greer PJ, et al. PET imaging of serotonin 1A receptor binding in depression. Biological Psychiatry. 1999;46(10):1375–1387
  18. Drevets WC, Thase ME, Moses-Kolko EL, Price J, Frank E, Kupfer DJ, et al. Serotonin-1A receptor imaging in recurrent depression: replication and literature review. Nuclear Medicine and Biology. 2007;34(7):865–877
  19. Evans DL, Charney DS. Mood disorders and medical illness: a major public health problem. Biological Psychiatry. 2003;54(3):177–180
  20. Feer H. The catecholamine hypothesis of depressions: further arguments. Comprehensive Psychiatry. 1967;8(1):1–6
  21. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, et al. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Archives of General Psychiatry. 1991;48(9):851–855
  22. Frazer, A., Hensler, J.G., and (1999). 13. Serotonin. Basic neurochemistry: molecular, cellular, and medical aspects. G. J. Siegel. Philadelphia, Lippincott Williams & Wilkins: xxi, 1183.
  23. Friston K, Holmes A, Worsley K, Poline J, Frith C, Frackowiak R. Statistical parametric maps in functional imaging: a general linear approach. Human Brain Mapping. 1995;2:189–210
  24. Friston KJ. Statistical parametric mapping. In:  Thatcher Robert W,  Hallett Mark, et al. editor. Functional neuroimaging: Technical foundations. 1994;p. 79–93xx, 303.
  25. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry. 1960;23:56–62
  26. Jacobs BL, Fornal CA. 5-HT and motor control: a hypothesis. Trends Neurosciences. 1993;16(9):346–352
  27. Joensuu M, Tolmunen T, Saarinen PI, Tiihonen J, Kuikka J, Ahola P, et al. Reduced midbrain serotonin transporter availability in drug-naive patients with depression measured by SERT-specific [(123)I] nor-beta-CIT SPECT imaging. Psychiatry Research. 2007;154(2):125–131
  28. Kegeles LS, Malone KM, Slifstein M, Ellis SP, Xanthopoulos E, Keilp JG, et al. Response of cortical metabolic deficits to serotonergic challenge in familial mood disorders. American Journal of Psychiatry. 2003;160(1):76–82
  29. Kennedy SH, Evans KR, Kruger S, Mayberg HS, Meyer JH, McCann S, et al. Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. American Journal of Psychiatry. 2001;158(6):899–905
  30. Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). Jama. 2003;289(23):3095–3105
  31. Ketter TA, Kimbrell TA, George MS, Willis MW, Benson BE, Danielson A, et al. Baseline cerebral hypermetabolism associated with carbamazepine response, and hypometabolism with nimodipine response in mood disorders. Biological Psychiatry. 1999;46(10):1364–1374
  32. Kimbrell TA, Little JT, Dunn RT, Frye MA, Greenberg BD, Wassermann EM, et al. Frequency dependence of antidepressant response to left prefrontal repetitive transcranial magnetic stimulation (rTMS) as a function of baseline cerebral glucose metabolism. Biological Psychiatry. 1999;46(12):1603–1613
  33. Koutsky CD, Mulvahill JE, Orbuch MW. Danger of depression associated with Rauwolfia therapy. Journal-lancet. 1962;82:346–349
  34. Kugaya A, Sanacora G, Staley JK, Malison RT, Bozkurt A, Khan S, et al. Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological Psychiatry. 2004;56(7):497–502
  35. Kur'Ianova EI. [The therapy of patients of hypertension with Rauwolfia serpentina preparations. Part 1. Preliminary results of therapy.]. Trudy Leningradskogo Sanitarno-GigienicÏeskogo Medicinskogo Instituta. 1959;48:169–183
  36. Laasonen-Balk T, Viinamaki H, Kuikka JT, Husso-Saastamoinen M, Lehtonen J, Tiihonen J. 123I-beta-CIT binding and recovery from depression. A six-month follow-up study. European Archives of Psychiatry and Clinical Neuroscience. 2004;254(3):152–155
  37. Lehto S, Tolmunen T, Joensuu M, Saarinen PI, Vanninen R, Ahola P, et al. Midbrain binding of [123I]nor-beta-CIT in atypical depression. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2006;30(7):1251–1255
  38. Lehto SM, Tolmunen T, Joensuu M, Saarinen PI, Valkonen-Korhonen M, Vanninen R, et al. Changes in midbrain serotonin transporter availability in atypically depressed subjects after one year of psychotherapy. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2008;32(1):229–237
  39. Lemonde S, Du L, Bakish D, Hrdina P, Albert PR. Association of the C(-1019)G 5-HT1A functional promoter polymorphism with antidepressant response. International Journal of Neuropsychopharmacology. 2004;7(4):501–506
  40. Little JT, Ketter TA, Kimbrell TA, Danielson A, Benson B, Willis MW, et al. Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls. Psychopharmacology Bulletin. 1996;32(4):629–635
  41. Little JT, Ketter TA, Kimbrell TA, Dunn RT, Benson BE, Willis MW, et al. Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. Biological Psychiatry. 2005;57(3):220–228
  42. Mann JJ. The medical management of depression. N. Engl. J. Med. 2005;353(17):1819–1834
  43. Mann JJ, Malone KM, Diehl DJ, Perel J, Cooper TB, Mintun MA. Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients. American Journal of Psychiatry. 1996;153(2):174–182
  44. Mann JJ, Malone KM, Diehl DJ, Perel J, Nichols TE, Mintun MA. Positron emission tomographic imaging of serotonin activation effects on prefrontal cortex in healthy volunteers. Journal of Cerebral Blood Flow and Metabolism. 1996;16(3):418–426
  45. Mayberg HS. Limbic–cortical dysregulation: a proposed model of depression. Journal of Neuropsychiatry and Clinical Neurosciences. 1997;9(3):471–481
  46. Mayberg HS, Brannan SK, Mahurin RK, Jerabek PA, Brickman JS, Tekell JL, et al. Cingulate function in depression: a potential predictor of treatment response. Neuroreport. 1997;8(4):1057–1061
  47. Meyer JH, Ginovart N, Boovariwala A, Sagrati S, Hussey D, Garcia A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Archives of General Psychiatry. 2006;63(11):1209–1216
  48. Michaud CM, Murray CJ, Bloom BR. Burden of disease—implications for future research. Jama. 2001;285(5):535–539
  49. Milak MS, Parsey RV, Keilp J, Oquendo MA, Malone KM, Mann JJ. Neuroanatomic correlates of psychopathologic components of major depressive disorder. Archives of General Psychiatry. 2005;62(4):397–408
  50. Miller JM, Oquendo MA, Ogden RT, Hu X, Goldman D, Huang YY, et al. Brain serotonin transporter and serotonin transporter polymorphism genotype predict one year remission from major depression. Biological Psychiatry. 2006;59(8):98S-98S
  51. Miller JM, Oquendo MA, Ogden RT, Mann JJ, Parsey RV. Serotonin transporter binding as a possible predictor of one-year remission in major depressive disorder. Journal of Psychiatric Research. 2008;
  52. Morris JS, Smith KA, Cowen PJ, Friston KJ, Dolan RJ. Covariation of activity in habenula and dorsal raphe nuclei following tryptophan depletion. Neuroimage. 1999;10(2):163–172
  53. Newberg AB, Amsterdam JD, Wintering N, Ploessl K, Swanson RL, Shults J, et al. 123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. Journal of Nuclear Medicine. 2005;46(6):973–977
  54. Nobler MS, Oquendo MA, Kegeles LS, Malone KM, Campbell CC, Sackeim HA. Decreased regional brain metabolism after ect. American Journal of Psychiatry. 2001;158(2):305–308
  55. Oquendo MA, Malone KM, Ellis SP, Sackeim HA, Mann JJ. Inadequacy of antidepressant treatment for patients with major depression who are at risk for suicidal behavior. American Journal of Psychiatry. 1999;156(2):190–194
  56. Oquendo MA, Baca-Garcia E, Kartachov A, Khait V, Campbell CE, Richards M, et al. A computer algorithm for calculating the adequacy of antidepressant treatment in unipolar and bipolar depression. Journal of Clinical Psychiatry. 2003;64(7):825–833
  57. Oquendo MA, Placidi GP, Malone KM, Campbell C, Keilp J, Brodsky B, et al. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge and lethality of suicide attempts in major depression. Archives of General Psychiatry. 2003;60(1):14–22
  58. Oquendo MA, Krunic A, Parsey RV, Milak M, Malone KM, Anderson A, et al. Positron emission tomography of regional brain metabolic responses to a serotonergic challenge in major depressive disorder with and without borderline personality disorder. Neuropsychopharmacology. 2005;30(6):1163–1172
  59. Panel DG. Depression in primary care. In: Vol. 2 Treatment of Major Depression. Clinical Practice Guideline, Number 5. Rockville, MD: US Department of Health and Human Services; 1999;
  60. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT1A receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology. 2006;31(8):1745–1749
  61. Parsey RV, Olvet DM, Oquendo MA, Huang YY, Ogden RT, Mann JJ. Higher 5-HT(1A) receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology. 2006;
  62. Prudic J, Haskett RF, Mulsant B, Malone KM, Pettinati HM, Stephens S, et al. Resistance to antidepressant medications and short-term clinical response to ECT. American Journal of Psychiatry. 1996;153(8):985–992
  63. Rausch JL, Johnson ME, Fei YJ, Li JQ, Shendarkar N, Hobby HM, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biological Psychiatry. 2002;51(9):723–732
  64. Reimold M, Batra A, Knobel A, Smolka MN, Zimmer A, Mann K, et al. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [(11)C]DASB PET study. Molecular Psychiatry. 2008;
  65. Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. Journal of Clinical Psychopharmacology. 1990;10(2):96–104
  66. Saxena S, Brody AL, Ho ML, Zohrabi N, Maidment KM, Baxter LR. Differential brain metabolic predictors of response to paroxetine in obsessive–compulsive disorder versus major depression. American Journal of Psychiatry. 2003;160(3):522–532
  67. Schildkraut JJ. The catecholamine hypothesis of affective disorders. A review of supporting evidence. International Journal of Psychiatry. 1967;4(3):203–217
  68. Smith WT, Londborg PD, Glaudin V, Painter JR. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?. Journal of affective Disorders. 2002;70(3):251–259
  69. Stein L. Effects and interactions of imipramine, chlorpromazine, reserpine and amphetamine on self-stimulation: possible neurophysiological basis of depression. Recent Advances in Biological Psychiatry. 1961;4:288–309
  70. Uusitalo AL, Valkonen-Korhonen M, Helenius P, Vanninen E, Bergstrom KA, Kuikka JT. Abnormal serotonin reuptake in an overtrained, insomnic and depressed team athlete. International Journal of Sports Medicine. 2004;25(2):150–153
  71. van Praag HM, Kits TP, Schut T, Dijkstra P. An attempt at indirect evaluation of the noradrenaline hypothesis. Results of a pilot study of the antidepressive qualities of p-chloro-N-methylamphetamine. Behavioral Neuropsychiatry. 1969;1(5):17–24
  72. Walter U, Hoeppner J, Prudente-Morrissey L, Horowski S, Herpertz SC, Benecke R. Parkinson's disease-like midbrain sonography abnormalities are frequent in depressive disorders. Brain. 2007;130(Pt 7):1799–1807
  73. Willeit M, Praschak-Rieder N, Neumeister A, Pirker W, Asenbaum S, Vitouch O, et al. [123I]-beta-CIT SPECT imaging shows reduced brain serotonin transporter availability in drug-free depressed patients with seasonal affective disorder. Biological Psychiatry. 2000;47(6):482–489
  74. Wright IC, McGuire PK, Poline JB, Travere JM, Murray RM, Frith CD, et al. A voxel-based method for the statistical analysis of gray and white matter density applied to schizophrenia. Neuroimage. 1995;2(4):244–252
  75. Wu J, Buchsbaum MS, Gillin JC, Tang C, Cadwell S, Wiegand M, et al. Prediction of antidepressant effects of sleep deprivation by metabolic rates in the ventral anterior cingulate and medial prefrontal cortex. American Journal of Psychiatry. 1999;156(8):1149–1158
  76. Wu JC, Gillin JC, Buchsbaum MS, Hershey T, Johnson JC, Bunney WE. Effect of sleep deprivation on brain metabolism of depressed patients. American Journal of Psychiatry. 1992;149(4):538–543

PII: S0925-4927(08)00141-8

doi: 10.1016/j.pscychresns.2008.09.004

Psychiatry Research: Neuroimaging
Volume 173, Issue 1 , Pages 63-70 , 15 July 2009

Article Tools

* Image Usage & Resolution